Intralymphatic administration of BCG in melanoma patients

Natale Cascinelli; Gian Paolo Balzarini; Vincenzo Fontana; Sergio Orefice; Umberto Veronesi

doi:10.1007/BF00205432

Intralymphatic administration of BCG in melanoma patients

Natale Cascinelli, Gian Paolo Balzarini, Vincenzo Fontana, Sergio Orefice, Umberto Veronesi

Istituto Europeo di Oncologia

Research output: Contribution to journal › Article › peer-review

Abstract

From November 1973 to December 1974, 20 patients with advanced malignant melanoma were treated with BCG given by intralymphatic route at the Cancer Institute of Milan. The lyophilized Pasteur BCG was used. Patients were treated with a single dose ranging from 0.2-80 mg. Patients' performance status was never severely impaired. The most frequent side effects were fever, lymphangitis, and lymph node enlargement. Variations were observed in white cell count, ERS and immunoglobulins; in no case did we find evidence of liver toxicity or tumor growth enhancement. It is concluded that the intralymphatic route is a safe way of administrating BCG.

Original language	English
Pages (from-to)	157-161
Number of pages	5
Journal	Cancer Immunology, Immunotherapy
Volume	2
Issue number	3
DOIs	https://doi.org/10.1007/BF00205432
Publication status	Published - 1977

ASJC Scopus subject areas

Cancer Research
Immunology
Oncology

Access to Document

10.1007/BF00205432

Fingerprint Dive into the research topics of 'Intralymphatic administration of BCG in melanoma patients'. Together they form a unique fingerprint.

Cite this

@article{cb64f998c9d54d7db0df52b45f9e6623,

title = "Intralymphatic administration of BCG in melanoma patients",

abstract = "From November 1973 to December 1974, 20 patients with advanced malignant melanoma were treated with BCG given by intralymphatic route at the Cancer Institute of Milan. The lyophilized Pasteur BCG was used. Patients were treated with a single dose ranging from 0.2-80 mg. Patients' performance status was never severely impaired. The most frequent side effects were fever, lymphangitis, and lymph node enlargement. Variations were observed in white cell count, ERS and immunoglobulins; in no case did we find evidence of liver toxicity or tumor growth enhancement. It is concluded that the intralymphatic route is a safe way of administrating BCG.",

author = "Natale Cascinelli and Balzarini, {Gian Paolo} and Vincenzo Fontana and Sergio Orefice and Umberto Veronesi",

year = "1977",

doi = "10.1007/BF00205432",

language = "English",

volume = "2",

pages = "157--161",

journal = "Cancer Immunology and Immunotherapy",

issn = "0340-7004",

publisher = "Springer Science and Business Media Deutschland GmbH",

number = "3",

}

TY - JOUR

T1 - Intralymphatic administration of BCG in melanoma patients

AU - Cascinelli, Natale

AU - Balzarini, Gian Paolo

AU - Fontana, Vincenzo

AU - Orefice, Sergio

AU - Veronesi, Umberto

PY - 1977

Y1 - 1977

N2 - From November 1973 to December 1974, 20 patients with advanced malignant melanoma were treated with BCG given by intralymphatic route at the Cancer Institute of Milan. The lyophilized Pasteur BCG was used. Patients were treated with a single dose ranging from 0.2-80 mg. Patients' performance status was never severely impaired. The most frequent side effects were fever, lymphangitis, and lymph node enlargement. Variations were observed in white cell count, ERS and immunoglobulins; in no case did we find evidence of liver toxicity or tumor growth enhancement. It is concluded that the intralymphatic route is a safe way of administrating BCG.

AB - From November 1973 to December 1974, 20 patients with advanced malignant melanoma were treated with BCG given by intralymphatic route at the Cancer Institute of Milan. The lyophilized Pasteur BCG was used. Patients were treated with a single dose ranging from 0.2-80 mg. Patients' performance status was never severely impaired. The most frequent side effects were fever, lymphangitis, and lymph node enlargement. Variations were observed in white cell count, ERS and immunoglobulins; in no case did we find evidence of liver toxicity or tumor growth enhancement. It is concluded that the intralymphatic route is a safe way of administrating BCG.

UR - http://www.scopus.com/inward/record.url?scp=0017653087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017653087&partnerID=8YFLogxK

U2 - 10.1007/BF00205432

DO - 10.1007/BF00205432

M3 - Article

AN - SCOPUS:0017653087

VL - 2

SP - 157

EP - 161

JO - Cancer Immunology and Immunotherapy

JF - Cancer Immunology and Immunotherapy

SN - 0340-7004

IS - 3

ER -